Microcosting Analysis of Diffuse Large B-Cell Lymphoma Treatment in Malawi | Zendy

Matthew Painschab | Zendy; Racquel E. Kohler | Zendy; Edwards Kasonkanji | Zendy; Takondwa Zuze | Zendy; Bongani Kaimila | Zendy; Richard Nyasosela | Zendy; Ruth Nyirenda | Zendy; Robert Krysiak | Zendy; Satish Gopal | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Microcosting Analysis of Diffuse Large B-Cell Lymphoma Treatment in Malawi

Author(s) -

Matthew Painschab,

Racquel E. Kohler,

Edwards Kasonkanji,

Takondwa Zuze,

Bongani Kaimila,

Richard Nyasosela,

Ruth Nyirenda,

Robert Krysiak,

Satish Gopal

Publication year - 2019

Publication title -

journal of global oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.002

H-Index - 17

ISSN - 2378-9506

DOI - 10.1200/jgo.19.00059

Subject(s) - medicine , ifosfamide , diffuse large b cell lymphoma , chop , context (archaeology) , salvage therapy , rituximab , gemcitabine , oncology , etoposide , chemotherapy , lymphoma , biology , paleontology

To describe the cost of treating diffuse large B-cell lymphoma (DLBCL) in Malawi under the following circumstances: (1) palliation only, (2) first-line cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP), (3) salvage etoposide, ifosfamide, and cisplatin (EPIC), and (4) salvage gemcitabine and oxaliplatin (GEMOX).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research